As­traZeneca, Mer­ck cull one Lyn­parza in­di­ca­tion in heav­i­ly pre­treat­ed ovar­i­an can­cer pa­tients

Just one day af­ter block­buster Lyn­parza got ac­cess to an­oth­er in­di­ca­tion in Chi­na, its Big Phar­ma own­ers have de­cid­ed to with­draw it in cer­tain pa­tients …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER